Concerning cutaneous manifestations, specifically bullous pemphigoid, retrospective analysis of over 9,000 patients treated in Japan (2009–2017) associated it with DPP-IV inhibitors, particularly vildagliptin (Kawaguchi et al., 2019). This evidence concerns the gene DPP4 and bullous pemphigoid.